130 related articles for article (PubMed ID: 38744818)
1. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.
Rodrigues JS; Chenlo M; Bravo SB; Perez-Romero S; Suarez-Fariña M; Sobrino T; Sanz-Pamplona R; González-Prieto R; Blanco Freire MN; Nogueiras R; López M; Fugazzola L; Cameselle-Teijeiro JM; Alvarez CV
Nat Commun; 2024 May; 15(1):3736. PubMed ID: 38744818
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract][Full Text] [Related]
3. SUMO-activated target traps (SATTs) enable the identification of a comprehensive E3-specific SUMO proteome.
Salas-Lloret D; Jansen NS; Nagamalleswari E; van der Meulen C; Gracheva E; de Ru AH; Otte HAM; van Veelen PA; Pichler A; Goedhart J; Vertegaal ACO; González-Prieto R
Sci Adv; 2023 Aug; 9(31):eadh2073. PubMed ID: 37531430
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Insights of Thyroid Cancer Progression.
Leandro-García LJ; Landa I
Endocrinology; 2023 Aug; 164(9):. PubMed ID: 37503738
[TBL] [Abstract][Full Text] [Related]
5. In vivo hematopoietic stem cell modification by mRNA delivery.
Breda L; Papp TE; Triebwasser MP; Yadegari A; Fedorky MT; Tanaka N; Abdulmalik O; Pavani G; Wang Y; Grupp SA; Chou ST; Ni H; Mui BL; Tam YK; Weissman D; Rivella S; Parhiz H
Science; 2023 Jul; 381(6656):436-443. PubMed ID: 37499029
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of cancers derived from thyroid follicular cells.
Fagin JA; Krishnamoorthy GP; Landa I
Nat Rev Cancer; 2023 Sep; 23(9):631-650. PubMed ID: 37438605
[TBL] [Abstract][Full Text] [Related]
7. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.
Szklarczyk D; Kirsch R; Koutrouli M; Nastou K; Mehryary F; Hachilif R; Gable AL; Fang T; Doncheva NT; Pyysalo S; Bork P; Jensen LJ; von Mering C
Nucleic Acids Res; 2023 Jan; 51(D1):D638-D646. PubMed ID: 36370105
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.
Hofmann MC; Kunnimalaiyaan M; Wang JR; Busaidy NL; Sherman SI; Lai SY; Zafereo M; Cabanillas ME
Endocr Relat Cancer; 2022 Nov; 29(11):R173-R190. PubMed ID: 35975971
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic Thyroid Cancer: New Horizons and Challenges.
Maniakas A; Zafereo M; Cabanillas ME
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):391-401. PubMed ID: 35662448
[TBL] [Abstract][Full Text] [Related]
10. βIII-Tubulin Gene Regulation in Health and Disease.
Duly AMP; Kao FCL; Teo WS; Kavallaris M
Front Cell Dev Biol; 2022; 10():851542. PubMed ID: 35573698
[TBL] [Abstract][Full Text] [Related]
11. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT; Mahiny AJ; Vlatkovic I
Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
[TBL] [Abstract][Full Text] [Related]
13. Effects of aneuploidy on cell behaviour and function.
Li R; Zhu J
Nat Rev Mol Cell Biol; 2022 Apr; 23(4):250-265. PubMed ID: 34987171
[TBL] [Abstract][Full Text] [Related]
14. The reactome pathway knowledgebase 2022.
Gillespie M; Jassal B; Stephan R; Milacic M; Rothfels K; Senff-Ribeiro A; Griss J; Sevilla C; Matthews L; Gong C; Deng C; Varusai T; Ragueneau E; Haider Y; May B; Shamovsky V; Weiser J; Brunson T; Sanati N; Beckman L; Shao X; Fabregat A; Sidiropoulos K; Murillo J; Viteri G; Cook J; Shorser S; Bader G; Demir E; Sander C; Haw R; Wu G; Stein L; Hermjakob H; D'Eustachio P
Nucleic Acids Res; 2022 Jan; 50(D1):D687-D692. PubMed ID: 34788843
[TBL] [Abstract][Full Text] [Related]
15. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.
Perez-Riverol Y; Bai J; Bandla C; García-Seisdedos D; Hewapathirana S; Kamatchinathan S; Kundu DJ; Prakash A; Frericks-Zipper A; Eisenacher M; Walzer M; Wang S; Brazma A; Vizcaíno JA
Nucleic Acids Res; 2022 Jan; 50(D1):D543-D552. PubMed ID: 34723319
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability and aneuploidy as causes of cancer drug resistance.
Lukow DA; Sheltzer JM
Trends Cancer; 2022 Jan; 8(1):43-53. PubMed ID: 34593353
[TBL] [Abstract][Full Text] [Related]
17. RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas.
Garcia-Rendueles AR; Chenlo M; Oroz-Gonjar F; Solomou A; Mistry A; Barry S; Gaston-Massuet C; Garcia-Lavandeira M; Perez-Romero S; Suarez-Fariña M; Pradilla-Dieste A; Dieguez C; Mehlen P; Korbonits M; Alvarez CV
Oncogene; 2021 Nov; 40(45):6354-6368. PubMed ID: 34588620
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
Kukkula A; Ojala VK; Mendez LM; Sistonen L; Elenius K; Sundvall M
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503213
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
